Y mAbs Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $26,495 | $18,461 | $22,798 | $19,931 |
Gross Profit | 18,653 | 16,213 | 19,784 | 17,784 |
EBITDA | -5,936 | -8,447 | -9,636 | -6,749 |
EBIT | -8,568 | -9,789 | -6,908 | |
Net Income | -6,790 | -6,998 | -9,249 | -6,629 |
Net Change In Cash | 26,495 | 18,461 | 22,798 | 19,931 |
Free Cash Flow | -1,870 | -10,665 | 298 | -3,477 |
Cash | 67,234 | 68,122 | 77,806 | 75,749 |
Basic Shares | 44,875 | 44,626 | 44,022 | 43,779 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $87,685 | $84,819 | $65,267 | $34,897 |
Gross Profit | 72,434 | 73,403 | 57,700 | 32,383 |
EBITDA | -31,201 | -24,937 | -93,972 | -114,651 |
EBIT | -25,672 | -94,811 | -115,433 | |
Net Income | -29,666 | -21,427 | -96,325 | -56,345 |
Net Change In Cash | 87,685 | 84,819 | 65,267 | 34,897 |
Cost of Revenue | 66,801 | |||
Free Cash Flow | -15,714 | -27,232 | -75,921 | -103,523 |
Cash | 67,234 | 78,637 | 105,762 | 181,564 |
Basic Shares | 44,328 | 43,645 | 43,703 | 43,181 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.15 |
2024-09-30 | -$0.16 |
2024-06-30 | -$0.21 |
2024-03-31 | -$0.15 |
